Royal London Asset Management Ltd. cut its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,737 shares of the company's stock after selling 1,201 shares during the period. Royal London Asset Management Ltd. owned about 0.05% of argenx worth $19,518,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in ARGX. Steward Partners Investment Advisory LLC boosted its stake in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock worth $234,000 after buying an additional 20 shares during the last quarter. SG Americas Securities LLC boosted its position in argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after purchasing an additional 21 shares during the last quarter. Farther Finance Advisors LLC boosted its position in argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after purchasing an additional 21 shares during the last quarter. Dynasty Wealth Management LLC grew its stake in argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company's stock valued at $416,000 after purchasing an additional 22 shares in the last quarter. Finally, Choreo LLC increased its position in shares of argenx by 4.4% during the 4th quarter. Choreo LLC now owns 551 shares of the company's stock worth $342,000 after purchasing an additional 23 shares during the last quarter. Institutional investors own 60.32% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the stock. William Blair restated an "outperform" rating on shares of argenx in a report on Friday, February 28th. Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Oppenheimer upped their price objective on argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Wedbush reiterated an "outperform" rating and set a $655.00 target price on shares of argenx in a research note on Tuesday, December 3rd. Finally, Wells Fargo & Company boosted their target price on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $687.00.
View Our Latest Analysis on argenx
argenx Trading Down 3.6 %
argenx stock traded down $21.86 during trading hours on Wednesday, reaching $583.66. 355,472 shares of the stock were exchanged, compared to its average volume of 283,129. The stock has a 50 day moving average of $632.24 and a two-hundred day moving average of $601.12. The company has a market cap of $35.46 billion, a P/E ratio of -663.25 and a beta of 0.59. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21.
argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.
About argenx
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
